复方嗜酸乳杆菌片联合蒙脱石散治疗小儿腹泻病的临床效果
|
摘要
目的研究小儿腹泻病采取复方嗜酸乳杆菌片+蒙脱石散治疗的价值。方法选择我院2015年6月～2018年8月纳入的60例小儿腹泻病患儿,按照随机数字表法分为研究组和对照组,每组各30例。研究组采取复方嗜酸乳杆菌片+蒙脱石散治疗,对照组采取蒙脱石散治疗,比较两组的治疗结果。结果研究组呕吐、腹痛、发热消失、脱水纠正及大便外观恢复时间短于对照组(P<0.05);研究组治疗总有效率为93.33%,明显高于对照组的80.00%(P<0.05);研究组不良反应总发生率为6.67%,与对照组的13.33%比较,差异无统计学意义(P>0.05)。结论复方嗜酸乳杆菌片+蒙脱石散用于小儿腹泻治疗效果明显,可缩短治疗时间,消除相关症状,增强治疗效果,避免不良反应产生,安全性高。
Objective To study the value of Compound Lactobacillus Acidophilus Tablets+Montmorillonite Powder in the treatment of diarrhea in children. Methods Sixty children with pediatric diarrhea admitted to our hospital from June 2015 to August 2018 were selected. They were divided into study group and control group according to random number table method, 30 cases in each group. The study group was given Compound Lactobacillus Acidophilus Tablets+Montmorillonite Powder. The control group was given Montmorillonite Powder alone. The treatment results of the two groups were compared. Results The time of disappearance of vomiting, abdominal pain and fever in the study group, as well as the time of dehydration correction, and the recovery of stool appearance were shorter than those in the control group(P<0.05). The total effective rate of the study group was 93.33%, which was significantly higher than that of the control group(80.00%, P<0.05); the total incidence of adverse reactions in the study group was 6.67%, and there was no significant difference compared with the 13.33% in the control group(P>0.05). Conclusion Compound Lactobacillus Acidophilus Tablets +Montmorillonite Powder is effective in the treatment of diarrhea in children, which can shorten the treatment time, promote the disappearance of related symptoms, enhance the therapeutic effect, avoid adverse reactions,and have high safety.
Objective To study the value of Compound Lactobacillus Acidophilus Tablets+Montmorillonite Powder in the treatment of diarrhea in children. Methods Sixty children with pediatric diarrhea admitted to our hospital from June 2015 to August 2018 were selected. They were divided into study group and control group according to random number table method, 30 cases in each group. The study group was given Compound Lactobacillus Acidophilus Tablets+Montmorillonite Powder. The control group was given Montmorillonite Powder alone. The treatment results of the two groups were compared. Results The time of disappearance of vomiting, abdominal pain and fever in the study group, as well as the time of dehydration correction, and the recovery of stool appearance were shorter than those in the control group(P<0.05). The total effective rate of the study group was 93.33%, which was significantly higher than that of the control group(80.00%, P<0.05); the total incidence of adverse reactions in the study group was 6.67%, and there was no significant difference compared with the 13.33% in the control group(P>0.05). Conclusion Compound Lactobacillus Acidophilus Tablets +Montmorillonite Powder is effective in the treatment of diarrhea in children, which can shorten the treatment time, promote the disappearance of related symptoms, enhance the therapeutic effect, avoid adverse reactions,and have high safety.
引文
[1]陈练,汤韶斌,华晓星,等.蒙脱石散联合复方嗜酸乳杆菌片治疗婴幼儿腹泻的临床疗效研究[J].中国妇幼保健,2015,30(18):3092-3093.
[2]袁雪,陈玺.复方嗜酸乳杆菌片联合蒙脱石散治疗婴幼儿肺炎抗生素相关性腹泻的临床研究[J].药物评价研究,2017,40(1):83-86.
[3]罗敏,孙婉莹,陈罗,等.口服补液盐Ⅲ联合复方嗜酸乳杆菌片治疗婴幼儿急性腹泻病的临床观察[J].湖南师范大学学报(医学版),2018,15(4):94-96.
[4]方鹤松,段恕诚,董宗祈,等.中国腹泻病的诊断治疗方案(1993年10月北京修订)[J].临床儿科杂志,2004,22(3):148.
[5]卢建华,刘晓律.双歧三联活菌片联合蒙脱石散治疗小儿腹泻疗效及对患儿免疫功能的影响[J].临床和实验医学杂志,2015,14(2):125-127.
[6]黄宗祈,方鹤松.全国腹泻病防治学术研讨会侧记[J].中国实用儿科杂志,1998,13(6):380.
[7]宋晓彤.双歧三联活菌片联合蒙脱石散对腹泻患儿预后的影响[J].中国生化药物杂志,2017,37(6):117-118,121.
[8]何火英.双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效研究[J].中华妇幼临床医学杂志(电子版),2015,11(3):338-341.
[9]夏芳.复方嗜酸乳杆菌片对儿童秋季腹泻的临床疗效观察[J].中国现代药物应用,2018,12(6):107-109.
[10]杨聂妃,樊慧苏,吴俊,等.布拉氏酵母菌散联合蒙脱石散治疗小儿急性腹泻的临床疗效与安全性[J].中国生化药物杂志,2016,36(6):179-181.
[11]黄丽.消旋卡多曲联合蒙脱石散治疗小儿腹泻的临床研究[J].中国临床药理学杂志,2016,32(16):1464-1467.
[12]彭双勤.益生菌类药物联合蒙脱石散对小儿腹泻血清学免疫指标的影响[J].山西医药杂志,2018,47(11):1237-1239.
[13]李琛.蒙脱石散联合双歧杆菌四联活菌片治疗小儿过敏性腹泻临床效果分析[J].中国医学前沿杂志(电子版),2016,8(4):82-84.
[14]魏冬梅.评价复方嗜酸乳杆菌片联合蒙脱石混悬液治疗轮状病毒性肠炎的临床疗效与安全性[J].心理医生,2018,24(12):125-126.
[15]徐前.微生态制剂治疗腺病毒性肠炎疗效观察[J].中国处方药,2016,14(8):68-69.
[16]Mejia A,Atehortua S,Florez ID,et al.Cost-effectiveness analysis of Zinc supplementation for treatment of acute diarrhea in children younger than 5 years in colombia[J].J Pediatr Gastroenterol Nutr,2015,60(4):515-520.
[2]袁雪,陈玺.复方嗜酸乳杆菌片联合蒙脱石散治疗婴幼儿肺炎抗生素相关性腹泻的临床研究[J].药物评价研究,2017,40(1):83-86.
[3]罗敏,孙婉莹,陈罗,等.口服补液盐Ⅲ联合复方嗜酸乳杆菌片治疗婴幼儿急性腹泻病的临床观察[J].湖南师范大学学报(医学版),2018,15(4):94-96.
[4]方鹤松,段恕诚,董宗祈,等.中国腹泻病的诊断治疗方案(1993年10月北京修订)[J].临床儿科杂志,2004,22(3):148.
[5]卢建华,刘晓律.双歧三联活菌片联合蒙脱石散治疗小儿腹泻疗效及对患儿免疫功能的影响[J].临床和实验医学杂志,2015,14(2):125-127.
[6]黄宗祈,方鹤松.全国腹泻病防治学术研讨会侧记[J].中国实用儿科杂志,1998,13(6):380.
[7]宋晓彤.双歧三联活菌片联合蒙脱石散对腹泻患儿预后的影响[J].中国生化药物杂志,2017,37(6):117-118,121.
[8]何火英.双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效研究[J].中华妇幼临床医学杂志(电子版),2015,11(3):338-341.
[9]夏芳.复方嗜酸乳杆菌片对儿童秋季腹泻的临床疗效观察[J].中国现代药物应用,2018,12(6):107-109.
[10]杨聂妃,樊慧苏,吴俊,等.布拉氏酵母菌散联合蒙脱石散治疗小儿急性腹泻的临床疗效与安全性[J].中国生化药物杂志,2016,36(6):179-181.
[11]黄丽.消旋卡多曲联合蒙脱石散治疗小儿腹泻的临床研究[J].中国临床药理学杂志,2016,32(16):1464-1467.
[12]彭双勤.益生菌类药物联合蒙脱石散对小儿腹泻血清学免疫指标的影响[J].山西医药杂志,2018,47(11):1237-1239.
[13]李琛.蒙脱石散联合双歧杆菌四联活菌片治疗小儿过敏性腹泻临床效果分析[J].中国医学前沿杂志(电子版),2016,8(4):82-84.
[14]魏冬梅.评价复方嗜酸乳杆菌片联合蒙脱石混悬液治疗轮状病毒性肠炎的临床疗效与安全性[J].心理医生,2018,24(12):125-126.
[15]徐前.微生态制剂治疗腺病毒性肠炎疗效观察[J].中国处方药,2016,14(8):68-69.
[16]Mejia A,Atehortua S,Florez ID,et al.Cost-effectiveness analysis of Zinc supplementation for treatment of acute diarrhea in children younger than 5 years in colombia[J].J Pediatr Gastroenterol Nutr,2015,60(4):515-520.